Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Gains from Sales and Divestitures (2017 - 2022)

Historic Gains from Sales and Divestitures for Arcus Biosciences (RCUS) over the last 6 years, with Q4 2022 value amounting to $500000.0.

  • Arcus Biosciences' Gains from Sales and Divestitures rose 3082.74% to $500000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $500000.0, marking a year-over-year increase of 3082.74%. This contributed to the annual value of $500000.0 for FY2022, which is 3082.74% up from last year.
  • As of Q4 2022, Arcus Biosciences' Gains from Sales and Divestitures stood at $500000.0, which was up 3082.74% from $382183.0 recorded in Q4 2021.
  • Over the past 5 years, Arcus Biosciences' Gains from Sales and Divestitures peaked at $500000.0 during Q4 2022, and registered a low of $6250.0 during Q4 2020.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $372774.0 (2019), whereas its average is $255225.0.
  • As far as peak fluctuations go, Arcus Biosciences' Gains from Sales and Divestitures tumbled by 9832.34% in 2020, and later soared by 601492.8% in 2021.
  • Arcus Biosciences' Gains from Sales and Divestitures (Quarter) stood at $14918.0 in 2018, then soared by 2398.82% to $372774.0 in 2019, then tumbled by 98.32% to $6250.0 in 2020, then soared by 6014.93% to $382183.0 in 2021, then skyrocketed by 30.83% to $500000.0 in 2022.
  • Its Gains from Sales and Divestitures was $500000.0 in Q4 2022, compared to $382183.0 in Q4 2021 and $6250.0 in Q4 2020.